Anti-Algics in the Therapeutic Response of Breast and Urological Cancers

Autor: Ana Catarina Matos, João Lorigo, Inês Alexandra Marques, Ana Margarida Abrantes, Matilde Jóia-Gomes, Pedro Sa-Couto, Ana Cristina Gonçalves, Ana Valentim, Edgar Tavares-Silva, Arnaldo Figueiredo, Ana Salomé Pires, Maria Filomena Botelho
Jazyk: angličtina
Rok vydání: 2023
Předmět:
Zdroj: International Journal of Molecular Sciences, Vol 25, Iss 1, p 468 (2023)
Druh dokumentu: article
ISSN: 25010468
1422-0067
1661-6596
39933474
DOI: 10.3390/ijms25010468
Popis: The effect of anti-algics on tumor progression and the overall survival of patients is controversial and remains unclear. Herein, we disclose the in vitro effects of the local anesthetics lidocaine, ropivacaine, and levobupivacaine on breast (MCF7), prostate (PC3, LNCaP), and bladder (TCCSUP, HT1376) cancer cell lines, both as monotherapy and in combination with standard-of-care therapeutics. Assays for cell proliferation, viability, death profile, and migration were performed. Additionally, we explored the clinical outcomes of opioid use through a cross-sectional study involving 200 metastatic prostate cancer patients. The main clinical data collected included the type of opioid therapy administered, dosage, treatment duration, disease progression, and overall survival. Results obtained demonstrate that treatment with local anesthetics has a promising selective anti-tumor effect on these types of cancer, with higher effects when associated with docetaxel. This points out the use of local anesthetics as an added value in the treatment of prostate carcinoma patients. Alternatively, chronic opioid use was correlated with reduced overall survival (p < 0.05) and progression-free survival (p < 0.05) at each treatment line in the observational study. While these results provide valuable insights, larger prospective studies are imperative to comprehensively evaluate the clinical impact of opioid analgesics in prostate cancer patients.
Databáze: Directory of Open Access Journals